KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Gross Margin (2016 - 2026)

Emergent BioSolutions has reported Gross Margin over the past 16 years, most recently at 53.88% for Q1 2026.

  • For Q1 2026, Gross Margin fell 630.0% year-over-year to 53.88%; the TTM value through Mar 2026 reached 54.24%, up 408.0%, while the annual FY2025 figure was 56.09%, 2137.0% up from the prior year.
  • Gross Margin for Q1 2026 was 53.88% at Emergent BioSolutions, up from 42.91% in the prior quarter.
  • Over five years, Gross Margin peaked at 99.7% in Q1 2022 and troughed at 6.94% in Q1 2023.
  • A 5-year average of 51.32% and a median of 52.19% in 2024 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: plummeted -9277bps in 2023 and later skyrocketed 4493bps in 2024.
  • Year by year, Gross Margin stood at 49.33% in 2022, then crashed by -33bps to 33.08% in 2023, then rose by 19bps to 39.39% in 2024, then grew by 9bps to 42.91% in 2025, then rose by 26bps to 53.88% in 2026.
  • Business Quant data shows Gross Margin for EBS at 53.88% in Q1 2026, 42.91% in Q4 2025, and 62.83% in Q3 2025.